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Poisoning morbidity and mortality is high in the developing world. Systems for care of poisoned patients differ
markedly between countries. In this paper a comparison of two very different systems for the care of poisoned
patients, is presented. Specifically, the role of poison centers and poison treatment centers in the US and Iran are
contrasted. A systematic literature search was undertaken utilizing the PubMed, Scopus, and Google Scholar and
the keywords “poison centers”, “treatment” “Iran” “United States of America” and 100 publications were identified.
From these, relevant data were found in 23 publications. The information was double-checked and data were
summarized herein.
We find that the system of the care of poisoned patients relies heavily on certified poison centers in the US and
that only a few hospitals have well developed medical toxicology services. In contrast, in Iran, the poison center
system is somehow less developed and the care of poisoned patients is provided in centralized high volume
hospital poison units.
Although both the US and Iran have highly developed systems for the care of poisoned patients they are distinctly
different. Comparative studies based on these systems could provide important data for developing countries with
more rudimentary poison control and treatment facilities.
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Poisoning is a very common cause of hospital admis-
sions and even death worldwide. It has been reported to
be the cause of death in as many as 593000 people in
the developing world annually (intentional and uninten-
tional) [1]. It is one of the most common causes of mor-
tality and morbidity in countries such as Bangladesh and
India. Every day in the United States (US), an average of
87 people are reported to die as a result of unintentional
poisoning, and another 2277 are treated in emergency
departments (EDs) [2]. In 2005, intentional and uninten-
tional poisonings led to $33.4 billion in medical and
productivity costs in the US [3].
In Iran no such statistics exist. However, clinical toxi-
cologists confront many intoxicated patients in the few
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reproduction in any medium, provided the orit is expected that the mortality rate due to poisoning
may be as many as 8 and 209 deaths for each 1,000 ward-
admitted and 1,000 ICU-admitted patients, respectively.
In fact, in Iran, the most common reason for hospitalization,
and the second cause of mortality in hospitalized patients,
is poisoning [4].
Although poisoning is a problem for all countries, its
profile of age, intention, and clinical presentation can
differ substantially. Similarly, there are profound diffe-
rences in the systems for the management of poisoned
patients in various countries. In developing countries, all
poisoned patients tend to be evaluated primarily in EDs,
with hospital admission if necessary. In contrast, in
European countries and the US, there has been an active
system of poison centers for at least 5 decades [5]. These
centers allow active initial contact by telephone and pro-
vide specialized advice by physicians, pharmacists and
nurses with specific training in clinical toxicology. How-
ever, US poison centers do not provide bedside patient
care. Rather, if hospitalization or ED evaluation is re-
quired, they triage patients to local hospitals. In contrast,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the US have medical toxicology services. Given this dif-
ference in the ways in which poisoned patients are man-
aged, we set out to evaluate the methods of triaging and
treating poisoned patients in Iran and compare it with
the way these patients are handled in the US. It is hoped
that a comparison of these two very different systems can
lead to subsequent evaluations of the strengths and
weaknesses of each and hence produce hypotheses on
the optimal method of triaging and poisoned patients.
Methods
PubMed central, Scopus, Google, and Google Scholar
were searched for the articles about poison treatment
centers in USA and Iran. Our keywords were “poison
centers”, “treatment”, “Iran”, and “United States of
America”. A total of 100 articles were retrieved by the
searches. Those from prior to 1995 were excluded. Of
the remainder, 23 were judged to be compatible with
our study aims. These studies were evaluated and rele-
vant data was abstracted and double checked by one of
authors and verified by two others.
Structure of poisoning treatment centers
Almost 40,000 physicians work in Iran; of them 30–50
are Medical Toxicologists (MTs). The MTs in Iran are
physicians who have mostly studied Toxicology,
Anesthesiology, Pediatrics, Internal Medicine, Forensic
Medicine, and Emergency Medicine in their residency
period and/or after the residency, they have passed a
clinical toxicology fellowship program. They are mainly
allocated to one of ten hospitals in Iran specialized in
the management of these poisonings [4]. The largest poi-
soning treatment centers of Iran are located at Loghman
Hakim Hospital of Tehran and Imam Reza Hospital of
Mashhad. Loghman Hakim Hospital’s poison center as
the largest one provides services to as many as 25,000
poisoned patients (in- or out-patient) a year [6]. Besides
to Loghman Hakim Hospital of Tehran and Imam Reza
Hospital of Mashhad, other hospitals skilled in the manage-
ment of the poisoned patients are Baharloo Hospital in
Tehran, Noor Hospital in Isfahan, Razi Hospital in
Ahwaz, Farshchian Hospital in Hamadan, and Ali-Asghar
Hospital in Shiraz, and some private clinics, etc. [6]. In
addition, poisoning management centers in Birjand, Arak,
Ghom, Ardabil, Tabriz, Sari and Rasht are developing [6].
In the US, there is only one center with a specialized
unit and allocated beds for the treatment of poi-
soned patients. That center is located in Harrisburg,
Pennsylvania, and is known as the Pinnacle Health
Toxicology Center. The bulk of the initial contact of
poisoned patients with specialized toxicology care in the
US comes from telephone contact with poison control
centers. These centers then triage patients who requirehospital evaluation to EDs of local Hospitals, most of
which do not have specialized medical services. The
current system of poison centers in the US relies on 5
components: 1. Regionalized poison information centers;
2. Training of poison center personnel and related health
caregivers; 3. Utilization of poison information data-
bases; 4. A national data collection system; and 5. A
“systems approach” to care at a professional, state, and
federal level.7 US Poison centers generally have three
major goals: A. Primary prevention by activities such as
identification of high frequency and low morbidity toxic-
ities using their surveillance system, identification of the
products that need protective packaging, and creation of
necessary lay education programs; B. Secondary preven-
tion by promoting public knowledge of the availability of
the high quality poison centers, utilization of a uniform
telephone number to call in the US, professional aware-
ness of accurate data sources, well-trained professional
staffing poison centers on a 24 hour per day basis, effect-
ive coordination with emergency medical services, and
knowledge of the local availability for antidotes and spe-
cialized services such as hemodialysis; and C. Tertiary pre-
vention by advising callers of interventions that minimize
the severity of exposures, alerting emergency services, and
triaging patients to hospitals if necessary [7].
In US, when a call is initiated to a poison center, the
caller is quickly connected to a certified Specialist in
Poison Information (CSPI) [8]. Professionals in US
poison centers have access to poisoning databases such
as Micromedex/Poisondex and consensus guidelines
containing triage recommendations produced by the
American Association of poison Control Centers
(AAPC) published in Clinical Toxicology. This referral
to hospitals is based on the substances to which the
caller was exposed, the dose, and the caller’s symptoms
[9]. One important goal of US poison centers is to deter-
mine when triage to a hospital is not indicated. Because
inpatient or ED care in the US is very expensive, by
keeping patients out of hospitals poison centers can po-
tentially save significant amounts of money.
Structure of poison control centers
Although there were some plans to develop a national
toxicology information system as far back as 1985, the
first official drug and poison information center (DPIC)
was successfully established in Iran in 1995 [6] under
the auspices of Ministry of Health and Medical Educa-
tion and cooperation of nationwide Medical Universities
[10]. Currently, there are about 30 DPICs in Iran lo-
cated in various cities such as Tehran, Ahwaz, Ardabil,
Isfahan, Karaj, Kerman, Khorramabad, Mashhad,
Sanandaj, Shiraz, Tabriz, Yazd, etc., each of them cover-
ing a mean population of almost 2.5 million people [11].
Most of these centers are operative from 8 AM to 8 PM,
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cluding all holidays. Most of DPICs are staffed with MD
residents in toxicology and pharmacology or PharmD
residents in toxicology, pharmacology, clinical pharmacy,
or related sciences. The staff is available to offer advice
to all callers with relating to drug information and poi-
soning cases. This information is available to both public
and health professionals. Iranian centers also use caller
information for toxico-surveillance. DPICs both provide
answers to enquiries, and in cases of needing referral to
EDs, these are made to hospitals with medical toxicology
services. This kind of triaging is done to assure that poi-
soned patients receive the optimal possible care. DPICs
also function to increase the knowledge of the health
professionals and general public in various ways. To
reach this objective, they use media and hold specific
meetings in conjunction with major societies such as
Iranian Society of Toxicology (IranTox).
In the USA, the story is far different. The first US poi-
son center was established in Chicago in 1952. That
event ushered in an area of proliferation of many other
such centers. Their initial goal was to provide telephone
services to the public. The orientation of these early cen-
ters was distinctly pediatric because most of their calls
tended to involve potential exposures to children. Even-
tually a national network of such centers was developed
under the auspices of the American Association of
Poison Control Centers (AAPCC). That led to the estab-
lishment of a national data collection system. Originally
known as the Toxic Exposure Surveillance System
(TESS) [12], its most recent rendition is the National
Poison Data System (“NPDS”). All US centers use elec-
tronic medical records while simultaneously uploading
the data collection fields to the NPDS [8]. Over time, as
poison centers have grown, the sophistication of their
role has been expanded. This has been accomplished by
the development of strict accreditation standards for
poison centers and a certification examination for CSPIs.
Although the latter are commonly registered nurses or
pharmacists, some centers use individuals with other
qualifications. US CSPIs must be recertified every 7 years
[8]. Currently the primary goal of US poison centers
is to give telephone advice to both the public and to
health professionals. Other goals of US centers is to
educate the public regarding poison prevention, de-
tect and assist in the management of mass exposures,
and to serve as a sentinel system to detect trends
[13]. It is hoped that poison centers would reduce
healthcare costs. To maintain their accreditation US
poison centers must maintain strict standards and are
reviewed every 5 years [8].
Today, 57 AAPCC certified poison centers exist in US.
These centers were mostly located in the children’s
Hospitals in the past and their directors were generallypediatricians. This was because of the concern for poi-
soning morbidity and mortality in the children.
In 1972, there were 216 reported fatal childhood poi-
soning cases in US [8]. This number has already de-
clined to 39 children in 2007 [8]. Today about half of
the calls to US poison centers involve pediatric cases
[14]. In 2010, there were 3,952,722 encounters. Of these,
2,384,825 were human exposures, 94,823 calls were for
animal exposures and 1,466,253 were classified as infor-
mation calls [14]. US poison centers deal routinely with
a great diversity of poisonings including those involving
medications, illicit drug abuse, occupational exposures,
and attempted self-harm by various means [8]. Virtually
the entire US population has access to poison centers. In
contrast, in an Iranian study, it was shown that between
2006 and 2008, DIPC of Loghman Hakim Hospital re-
ceived a total of 9,694 calls [15].
Identity and characteristics of the callers
According to the Iranian study, most of the callers to
Iranian DIPCs are the patients’ relatives (49%) and are
female (61%). Most patients are in the age range of 18 to
40 years. In 45.2% of the cases, the patients themselves
called the DIPC. Most of the enquiries to Iranian poison
centers involve questions about drug indications (24%)
and adverse reactions (21.1%). The drugs most com-
monly involved are antidepressants (12.4%), antimicro-
bials (12%), and analgesics (11.2%). By providing answers
to these enquiries the DIPCs provide an important pub-
lic health service. However, medical caregivers’ calls are
much less common [15]. Although the exact reason for
the low rate of utilization of DPICs by medical profes-
sionals’ interest is not clear, Iranian physicians in general
desire not to be involved in the treatment of poisoned
patients. Rather they prefer to refer them to MTs. In
contrast to the systems in Iran and the US, poison cen-
ters in many countries limit the calls they receive to
healthcare providers and do not take calls from the pub-
lic [8]. Unlike Iran, the US public and health profes-
sionals are both well acquainted with the availability of
the poison center system.
Information resources
In Iranian DIPCs, queries questions are answered by the
use of several databases and books depending on their
availability [15]. Almost similar resources are relied on
by US poison centers. In addition, CSPIs always have
access to physicians sub-specialty trained in MT for
assistance with sick or complicated cases.
National poison data system
The NPDS described above has no analogy in Iran. Set-
ting up a system would be costly and labor intensive.
Presently there is no available funding for doing this.
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under the auspices of the AAPCC. Contained within this
collective dataset is the experience of the US poison cen-
ters from 1985 to date. It has been reported that almost
42%, 83%, and 100% of the US population have been
served by the poison centers in 1984, 1994, and 2003,
respectively [12]. Over the years, the system has be-
come more electronically-based and progressively more
sophisticated. When someone calls a poison center in
US, while giving needed information to the caller and
management of the case, data are entered into the sys-
tem by the CSPI using standardized AAPCC-mandated
procedures. The data collected from the caller include
case information, patient information (age, gender, and
weight), exposure information, clinical symptoms, ther-
apy strategies, and the outcome. The location of the
caller is also determined by postal codes or telephone
area code [12].
In the NPDS, the reason for exposure is classified as
intentional, unintentional, adverse reaction to a drug or
food, malicious exposure, suspected product contamin-
ation, or unknown. Clinical symptoms are classified using
a 131-item list and include cardiovascular (signs and symp-
toms such as bradycardia, hematemesis, pneumonitis,
hypoglycemia, etc.), dermal, gastrointestinal, hematologic/
hepatic, neurologic, respiratory, ocular, renal, and miscel-
laneous. Therapies (n = 58) and decontamination methods
(n = 10) are also noted and recorded. Medical outcome is
ascertained and classified as no effect, minor effect, mo-
derate effect, major effect, and death. Substances involved
are categorized using a 7-digit coding system provided
by the Poisindex database [12].
This AAPCC database has been shown to be effective
in supporting regulatory actions such as child resistant
closure on ethanol containing mouthwashes and re-
classification of prescription medications to over-the-counter
status. Hazards can be quantified in this database to
calculate hazard factors (by determining the serious
outcome per 1,000 exposures). However, the interpre-
tation of these factors is limited by the bias implicit in the
overall low morbidity of the caller population to US poi-
son centers.
Every day, US poison centers collectively receive almost
11,000 calls. Therefore, the volume of cases reflected in
the NPDS is huge. It is important to note that reports
taken by US poison centers are not mandatory, come from
many sources, are limited to the information provided by
callers or obtained at callbacks, and are not verified. These
factors limit the utility of the NPDS for scientific analyses
and studies.
Sources of support
In Iran, the expenses of DIPCs are generally provided by
the Ministry of Health and Medical Education or theUniversities in whose area the center is located. Because
these centers use part-time personnel and do not sup-
port a national data collection system, costs are low. In
contrast, maintaining the US system is costs approxi-
mately $136 million/year [16]. In the US, the costs of
poison center operations is generally provided by state
and local governments, Universities, Hospitals, chari-
table foundations, and the federal government. Cur-
rently, 12.6% of US poison center expenses are provided
by US government. The US federal budget has a large
deficit and in a cost cutting effort, there has been a 25%
reduction in the federal funding for poison centers [8].
While the US is currently undergoing a transformation
of its healthcare system, it is hoped that poison centers
will continue to be part of federal efforts to reduce the
costs and burden of poisonings to society [17].
As demonstrated over 15 years ago, the US public is
willing to support poison centers [18]. Investigators from
the California poison control system showed that by
blocking calls to poison centers, the general population
endorsed additional spending to continue to be served
by these centers [18]. While the US population supports
its poison centers, this is not the case in Iran, where pa-
tients simply prefer to go to hospitals without concern for
the additional costs imposed on the health care system.
Restricting public access to poison control centers
would result in additional costs to society, for several rea-
sons, including inappropriate use of hospital facilities [19].
These data suggest that although the cost of poison cen-
ters is high, their cost-effectiveness justifies their existence.
It is important to realize that the cost of healthcare in the
US is very high, so even small savings can have a large im-
pact. For example, the cost of an ED visit for a relatively
minor poisoning with no required inpatient hospitalization
could easily be in the range of $2,000 to 5,000. If a poison
center can prevent that one visit, the cost savings to the
individual and to society is large.
Effectiveness of the services
The network of US poison centers has been successful
in detecting the new poisoning outbreaks such as detec-
tion of the outbreak of fentanyl contaminated heroin
and cyanide-laced acetaminophen, as well as episodes of
food poisonings [8].
The network of 24 hours a day professionally staffed
centers could be called into action for other types of
public health activities and emergencies, for example
when they assumed the role of information centers in
diseases unrelated to poisoning such as during the re-
cent outbreak of influenza H1N1, thus reducing ED
costs of this disease dramatically [8]. The volume of calls
to the US system renders it a unique sentinel detection
system for natural or man-made outbreaks. When the
calls from a unique area exceeds which would be
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issue, an alert goes to MTs and to epidemiologists of the
US CDC and AAPCC for monitoring. Since such an effi-
cient cooperative system still does not exist in Iran, it is
not expected that Iranian poison centers could fill this
role.
Antidotal therapy
The above data on poison center use in the US and in
Iran may naturally raise the question of why these sys-
tems work so differently. The answer to this question is
clearly multi-factorial. In the US, there is a widely pro-
moted single telephone number that can be called from
any place in country. Numerous public education cam-
paigns, carried out both by local poison centers and the
AAPCC encourage the use of these centers. US poison
centers keep track of the availability of antidotes and
capabilities in Hospitals in their region. In general, how-
ever, they tend to triage patients to the nearest hospital
and most centers do not make an effort to refer specific-
ally to facilities where there are MT services. If needed
antidotes are not available at a particular hospital poison
centers may advise that hospital regarding the nearest
facilities where particular needed antidotes are available.
In contrast to the situation in the US, in Iran the
system for the management of poisoned patients is
highly centralized into specialized centers. Antidotes and
trained MTs tend to be clustered at these centers. In
2009, antidotes were reported to be used 83,000 times in
US [20]. According to the opinion of an expert consen-
sus panel (established in 2009), 24 antidotes are
recommended to be available in all Hospitals and an-
other nine have been recommended to be available
within a maximum of one hour [20]. Not all Hospitals in
the US comply with these unofficial recommendations
and it is here that the knowledge of antidote availability
by poison centers becomes important. The same goesTable 1 Differences between the management options of the
Management options Iran




Callers Female/18- to 40-yea
patients/mostly self-h
cases poisoned by antidep
Responders Mostly Residents of Toxi
or Clinical Pharmacy
Pharmacology and
Information Resources Mostly provided by b
and Internet resourc
TESS Absent
Costs Not been evaluated
Antidote availability Poor
Toxic Exposure Surveillance System (TESS); General physicians (GP).for Iran where maintaining a plentiful supply of anti-
dotes at all hospitals is impossible at present. For in-
stance, even some antidotes specified in the Iranian
Drug List (IDL) such as calcium disodium edetate, etha-
nol, fomepizole, digoxin antigen binding fragment (Fab),
mesoxalic acid, Prussian blue, and physostigmine sulfate
have not been always available in most hospitals [4]. Ap-
proximately one quarter of the IDL registered antidotes
are too expensive to be afforded by patients or their rela-
tives and thus are rarely used in Iran. On the other hand,
expensive antidotes such as fomepizole and Fabs are
extensively used in US, even in suspected cases of
methanol and digoxin toxicity, respectively. In Iran, the
IDL-registered antidotes are generally found only in
major referral hospitals serving as poison treatment cen-
ters in each province [20]. Lack of antidotes in some
hospitals is one reason why some Iranian physicians are
reluctant to manage poisoned patients and why they pre-
fer to refer these patients to poison treatment centers.
This also is one explanation for the few calls from health
care professionals to the DIPCs. If antidote availability
was increased, and professional education in MT was
broadened, a system for the care of poisoned patients
similar to that used in the US might be feasible. Doing
so would decrease over-crowding of Iranian toxicology
EDs. These changes, however, would require a major
investment in the Iranian healthcare system.
Toxicology training in Iran and USA
In both Iran and the US, there is an active system of
continuing medical education programs in clinical toxi-
cology [21]. The need for integration of MT education
within undergraduate and postgraduate clinical training
programs to maximize the care provided to poisoned pa-
tients has been recognized in Iran in the last decade.
Therefore, training in MT is now being integrated into
internships and in medical schools during the teachingpoisoned patients in Iran and US
US




Female/children patients (52% of the calls)/mostly poisoned





Nurses or pharmacists specialist in poison information
ooks
es
Provided from the national poison database
Present
yet 81 million dollars a year but proved to be cost-effective
Although not quite compatible with standards,
far better than Iran
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MT has recently been established in some major poison
treatment centers of the country. These training
programs have demonstrated the popularity of MT
with physicians, particularly specialists in Emergency
Medicine, General Toxicology, Forensic Medicine,
Pediatrics, and Internal Medicine, etc. [22]. Pharmacists
or specialists of Toxicology are also actively participated
in the CME courses.
In the US, MT fellowship training impacts the career
of physicians by enhancing their academic opportunities
and allowing them to develop MT services. Certification
for physicians in MT in the US is technically under
the purview of the specialty of Emergency Medicine,
although physicians trained in other fields who complete
an accredited MT fellowship may become sub-specialty
certified. Currently, 63% of US Emergency Medicine
training programs have a MT on the faculty in the US
[22]. MT rotation is a requirement for just 76%, an
elective at 19%, and not available at 5% of Emergency
medicine programs. Specialties other than Emergency
Medicine tend to have little formal training in MT as part
of their curricula [22].
In general, although MT is highly developed in Iran
compared to most other Middle Eastern countries [23],
comparative analyses such as that presented herein and
by others can be used as a springboard for ideas to pro-
mote academic and clinical development of MT [10,23].
Table 1 shows differences between the management
options of the poisoned patients in Iran and USA.
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